Our Company was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name "Mankind Pharma Private Limited", pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi ("RoC"). Pursuant to the conversion of our Company to a public limited company and as approved by our Shareholders pursuant to a special resolution dated July 14, 2005 the name of our Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh certificate of incorporation on April 13, 2006.Major events and milestones:2004 Entered the chronic pharmaceutical segment with the launch of `Amlokind' tablets and `Glimestar'tablets amongst others2005 -Set up our first manufacturing facility at Paonta Sahib, Himachal Pradesh-Entered the ophthalmic pharmaceutical segment with the launch of `Lubistar Eye Drops' and `Tobastar Eye Drops' amongst others2007 -Entered the consumer healthcare segment with the launch of `Manforce' brand-Entered the animal healthcare segment with launch of `Bandykind' and `Ceftiforce' amongst othersRaised ? 720 million from Monet Limited2009 Set up our manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh2010 Launched `Preganews' brand in the consumer healthcare segment2012 Setup our first R&D centre at IMT Manesar, Haryana2014 -Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan)-Set up our manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh2015 -Incorporated our Subsidiary, Lifestar Pharma LLC in the US-Incorporated our Subsidiary, Mankind Pharma Pte. Limited in Singapore2017 Set up our manufacturing facility in Sikkim2018 Our manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time2019 Entered the female infertility segment with the launch of `Dydroboon' tablets2020 -Incorporated our Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal-Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of `Cilaheart' tablets and `Statpure' tablets-Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of `Zukanorm' tablets2021 -Incorporated our Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE-Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of `Mlife' tablets-Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of `Trugaba-NT' tablets and `Prebris-MNT' tablets2022 -Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited-Entered into transplant segment with the launch of `Pangraf Capsules' and `Mycept' tablets amongst others-Entered into oncology segment with the launch of `Pacliall' injection amongst others-Acquired the brands `Daffy' and `Combihale' from Dr. Reddy's Laboratories-Our Subsidiary, Mankind Life Sciences Private Limited acquired 90.00% of the issued, subscribed and paid-up share capital of Upakarma Ayurveda Private Limited. 2023 -Mankind Pharma Sets New Industry Standard with Unprecedented Display on Burj Khalifa, Reinforcing Commitment to Excellence. -Mankind Pharma announced its partnership with SpiceJet to raise awareness about DMF-grade API. -Mankind Pharma Product Prega News and Sonam Kapoor partners to transform from pregnancy detection card to pregnancy care solution. 2024 -Mankind Pharma Completes Landmark Acquisition of BSV. -Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab. -Mankind Pharma Launches 45-Day Healthcare Mission at Mahakumbh Serving Thousands of Pilgrims with Free Health Check-ups. -Mankind Pharma Prodct Healthok has joined hands with Bikanervala, (Multinational Indian Restaurant and Sweets Chain).